Physician profile
Satnam Singh
NPI 1568418416
$6,144.99
in general payments reported to CMS, 2019-2025
31 companies · $428 in 2025
The $428 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $634 · 2021: $926 · 2022: $1,200 · 2023: $1,184 · 2024: $972 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $785.74 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $640.15 | 2019-2025 | |
| Abbvie INC. | $579.07 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $578.32 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $407.42 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.66 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $352.82 | 2022-2024 | Infinity, Freestyle Libre 3 |
| Exact Sciences Corporation | $308.90 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $285.61 | 2019-2025 | Invega Sustenna |
| Glaxosmithkline, LLC. | $238.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $222.82 | 2020-2023 | Verquvo, Belsomra |
| Boston Scientific Corporation | $169.78 | 2019-2023 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $147.19 | 2022-2024 | Givlaari |
| Astrazeneca Pharmaceuticals LP | $122.10 | 2019-2024 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $119.58 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $115.26 | 2022 | |
| Eisai INC. | $110.41 | 2020-2024 | |
| Astellas Pharma US INC | $102.78 | 2019-2024 | Veozah |
| Biogen, INC. | $99.50 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $89.29 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.57 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $70.34 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.90 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $24.82 | 2024 | |
| Allergan, INC. | $22.61 | 2020 | |
| Idorsia Pharmaceuticals US INC | $18.70 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $16.18 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.54 | 2025 | Zoryve |
| Ardelyx, INC. | $14.41 | 2023 | Ibsrela |
| Inari Medical, INC. | $14.00 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Therapeuticsmd, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satnam Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.